Should I buy or sell Nektar Therapeutics stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last year. There are currently 2 sell ratings, 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "reduce" NKTR shares. View NKTR analyst ratings or view top-rated stocks .

What is Nektar Therapeutics' stock price target for 2024?

7 brokerages have issued 1-year price targets for Nektar Therapeutics' stock. Their NKTR share price targets range from $1.00 to $6.00. On average, they anticipate the company's share price to reach $3.00 in the next year. This suggests a possible upside of 485.9% from the stock's current price. View analysts price targets for NKTR or view top-rated stocks among Wall Street analysts .

How have NKTR shares performed in 2023?

Nektar Therapeutics' stock was trading at $2.26 at the start of the year. Since then, NKTR shares have decreased by 77.3% and is now trading at $0.5120. View the best growth stocks for 2023 here .

When is Nektar Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our NKTR earnings forecast .

How were Nektar Therapeutics' earnings last quarter?

Nektar Therapeutics (NASDAQ:NKTR) issued its quarterly earnings results on Tuesday, August, 8th. The biopharmaceutical company reported ($0.27) EPS for the quarter, beating analysts' consensus estimates of ($0.30) by $0.03. The biopharmaceutical company had revenue of $20.50 million for the quarter, compared to the consensus estimate of $20.94 million. Nektar Therapeutics had a negative net margin of 332.73% and a negative trailing twelve-month return on equity of 80.44%. During the same period in the previous year, the firm posted ($0.85) EPS.

What is Howard W. Robin's approval rating as Nektar Therapeutics' CEO?

46 employees have rated Nektar Therapeutics Chief Executive Officer Howard W. Robin on Glassdoor.com . Howard W. Robin has an approval rating of 81% among the company's employees.

What other stocks do shareholders of Nektar Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Micron Technology (MU) , NVIDIA (NVDA) , Alibaba Group (BABA) , Gilead Sciences (GILD) , Intel (INTC) , Pfizer (PFE) , Advanced Micro Devices (AMD) , Bristol-Myers Squibb (BMY) , Netflix (NFLX) and Incyte (INCY) .

Who are Nektar Therapeutics' major shareholders?

Nektar Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include RA Capital Management L.P. (9.80%), Acadian Asset Management LLC (4.00%), Primecap Management Co. CA (3.77%), Jacobs Levy Equity Management Inc. (2.57%), Monaco Asset Management SAM (2.53%) and AQR Capital Management LLC (1.92%). Insiders that own company stock include Curet Myriam, Gil M Labrucherie, Gil M Labrucherie , Howard W Robin, Howard W Robin , Jillian B Thomsen, Jillian B Thomsen , John Northcott , Jonathan Zalevsky , Karin Eastham, Mark Andrew Wilson , Myriam Curet , Robert Chess and Roy A Whitfield. View institutional ownership trends .

How do I buy shares of Nektar Therapeutics?

Shares of NKTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Nektar Therapeutics Stock Price, News & Analysis (NASDAQ:NKTR)

$0.51

0.00 (0.00%)

(As of 12/5/2023 ET)

Compare

Today's Range: $0.50
▼
$0.53
50-Day Range: $0.42
▼
$0.61
52-Week Range: $0.41
▼
$3.19

Volume: 649,061 shs
Average Volume: 4.16 million shs
Market Capitalization: $97.67 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.00

Nektar Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Reduce
1.86 Rating Score
Upside/Downside: 485.9% Upside
$3.00 Price Target
Short Interest: Bearish
4.20% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.77
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Selling Shares
$17,474 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.84) to ($0.78) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

270th out of 948 stocks

Pharmaceutical Preparations Industry

109th out of 421 stocks

2.9

Analyst's Opinion

Consensus Rating
Nektar Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.86, and is based on 1 buy rating, 4 hold ratings, and 2 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.00, Nektar Therapeutics has a forecasted upside of 485.9% from its current price of $0.51.
Amount of Analyst Coverage
Nektar Therapeutics has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
4.20% of the outstanding shares of Nektar Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Nektar Therapeutics has a short interest ratio ("days to cover") of 4.7.
Change versus previous month
Short interest in Nektar Therapeutics has recently increased by 7.23%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Nektar Therapeutics does not currently pay a dividend.
Dividend Growth
Nektar Therapeutics does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Nektar Therapeutics has received a 60.23% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Topoisomerase 1 (TOP1) inhibitors", "Clinical research services", and "Peripheral opioid receptor antagonists" products. See details.
Environmental Sustainability
The Environmental Impact score for Nektar Therapeutics is -1.77.

1.1

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Nektar Therapeutics this week, compared to 2 articles on an average week.
Search Interest
40 people have searched for NKTR on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.
MarketBeat Follows
3 people have added Nektar Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Nektar Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $17,474.00 in company stock.
Percentage Held by Insiders
Only 3.07% of the stock of Nektar Therapeutics is held by insiders.
Percentage Held by Institutions
82.20% of the stock of Nektar Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Nektar Therapeutics are expected to grow in the coming year, from ($0.84) to ($0.78) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Nektar Therapeutics is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Nektar Therapeutics is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Nektar Therapeutics has a P/B Ratio of 0.26. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Nektar Therapeutics Stock (NASDAQ:NKTR)

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

NKTR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NKTR Stock News Headlines

December 6, 2023 | americanbankingnews.com

StockNews.com Initiates Coverage on Nektar Therapeutics (NASDAQ:NKTR)

November 26, 2023 | americanbankingnews.com

Nektar Therapeutics (NASDAQ:NKTR) Given Consensus Rating of "Reduce" by Analysts

December 6, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 10, 2023 | benzinga.com

Nektar Therapeutics Stock (NASDAQ:NKTR) Earnings Dates and Earning Calls

November 10, 2023 | markets.businessinsider.com

Positive Report for Nektar Therapeutics (NKTR) from TD Cowen

November 10, 2023 | msn.com

TD Cowen Upgrades Nektar Therapeutics (NKTR)

November 9, 2023 | finance.yahoo.com

Nektar Therapeutics (NASDAQ:NKTR) Q3 2023 Earnings Call Transcript

November 8, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS) and Nektar Therapeutics (NKTR)

December 6, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

November 8, 2023 | finance.yahoo.com

Nektar Therapeutics (NKTR) Incurs Wider-Than-Expected Q3 Loss

November 7, 2023 | benzinga.com

Recap: Nektar Therapeutics Q3 Earnings

November 7, 2023 | markets.businessinsider.com

Nektar Therapeutics Q3 Loss decreases, but misses estimates

November 6, 2023 | benzinga.com

A Preview Of Nektar Therapeutics's Earnings

October 31, 2023 | finance.yahoo.com

Nektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial Markets

October 13, 2023 | finance.yahoo.com

Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress

October 5, 2023 | msn.com

Nektar Therapeutics (NKTR) Price Target Increased by 22.34% to 2.93

October 2, 2023 | finance.yahoo.com

Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy

September 27, 2023 | finance.yahoo.com

Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer

September 21, 2023 | benzinga.com

Director at Nektar Therapeutics Acquires Company Stock Options Worth 85,000 Shares

September 21, 2023 | benzinga.com

Nektar Therapeutics Board Member Awarded $59K Worth of Stock Options

September 13, 2023 | markets.businessinsider.com

Nektar Therapeutics Reports Promising Data From Phase 1b Study Of Rezpegaldesleukin

September 7, 2023 | finance.yahoo.com

Why Is Nektar (NKTR) Down 37.1% Since Last Earnings Report?

September 6, 2023 | finance.yahoo.com

Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th

August 18, 2023 | gurufocus.com

RA Capital Management, L.P. Acquires Significant Stake in Nektar Therapeutics

August 9, 2023 | finance.yahoo.com

Nektar Therapeutics (NKTR) Q2 Loss Narrows, Sales Miss

August 8, 2023 | markets.businessinsider.com

Nektar Therapeutics Q2 Loss decreases, beats estimates

August 8, 2023 | finance.yahoo.com

Nektar Therapeutics Reports Second Quarter 2023 Financial Results

See More Headlines

Receive NKTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/08/2023
Today: 12/06/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/27/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Sector: Medical
Current Symbol: NASDAQ:NKTR
CUSIP: 64026810
CIK: 906709
Web: www.nektar.com
Phone: (415) 482-5300
Fax: 415-339-5300
Employees: 216
Year Founded: 1990

Price Target and Rating

Average Stock Price Target: $3.00
High Stock Price Target: $6.00
Low Stock Price Target: $1.00
Potential Upside/Downside: +485.9%
Consensus Rating: Reduce
Rating Score (0-4): 1.86
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.56)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-368,200,000.00
Net Margins: -332.73%
Pretax Margin: -329.36%
Return on Equity: -80.44%
Return on Assets: -35.10%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.66
Quick Ratio: 7.37

Sales & Book Value

Annual Sales: $92.06 million
Price / Sales: 1.06
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.95 per share
Price / Book: 0.26

Miscellaneous

Outstanding Shares: 190,770,000
Free Float: 184,914,000
Market Cap: $97.67 million
Optionable: Optionable
Beta: 0.88

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Mr. Howard W. Robin (Age 70)
CEO, President & Director
Comp: $1.83M
Mr. Mark A. Wilson (Age 51)
Senior VP, Chief Legal Officer & Secretary
Comp: $749.99k
Dr. Jonathan Zalevsky Ph.D. (Age 48)
Senior VP & Chief Research and Development Officer
Comp: $1.25M
Ms. Sandra A. Gardiner (Age 57)
Chief Financial Officer
Vivian Wu
Director of Investor Relations & Corporate Affairs
Mr. Robert Bacci
Senior Vice President of Human Resources & Facilities Operations
Ms. Jennifer Ruddock
Chief Business Officer
Dr. Mary Tagliaferri L.Ac. (Age 57)
M.D., Chief Medical Officer
Dr. Loui T. Madakamutil
VP and Head of Discovery & Research

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NKTR Stock Analysis - Frequently Asked Questions

Should I buy or sell Nektar Therapeutics stock right now?: 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last year. There are currently 2 sell ratings, 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "reduce" NKTR shares.
View NKTR analyst ratings or view top-rated stocks.
What is Nektar Therapeutics' stock price target for 2024?: 7 brokerages have issued 1-year price targets for Nektar Therapeutics' stock. Their NKTR share price targets range from $1.00 to $6.00. On average, they anticipate the company's share price to reach $3.00 in the next year. This suggests a possible upside of 485.9% from the stock's current price.
View analysts price targets for NKTR or view top-rated stocks among Wall Street analysts.
How have NKTR shares performed in 2023?: Nektar Therapeutics' stock was trading at $2.26 at the start of the year. Since then, NKTR shares have decreased by 77.3% and is now trading at $0.5120.
View the best growth stocks for 2023 here.
When is Nektar Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our NKTR earnings forecast.
How were Nektar Therapeutics' earnings last quarter?: Nektar Therapeutics (NASDAQ:NKTR) issued its quarterly earnings results on Tuesday, August, 8th. The biopharmaceutical company reported ($0.27) EPS for the quarter, beating analysts' consensus estimates of ($0.30) by $0.03. The biopharmaceutical company had revenue of $20.50 million for the quarter, compared to the consensus estimate of $20.94 million. Nektar Therapeutics had a negative net margin of 332.73% and a negative trailing twelve-month return on equity of 80.44%. During the same period in the previous year, the firm posted ($0.85) EPS.

What is Howard W. Robin's approval rating as Nektar Therapeutics' CEO?: 46 employees have rated Nektar Therapeutics Chief Executive Officer Howard W. Robin on Glassdoor.com. Howard W. Robin has an approval rating of 81% among the company's employees.
What other stocks do shareholders of Nektar Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), Netflix (NFLX) and Incyte (INCY).
Who are Nektar Therapeutics' major shareholders?: Nektar Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include RA Capital Management L.P. (9.80%), Acadian Asset Management LLC (4.00%), Primecap Management Co. CA (3.77%), Jacobs Levy Equity Management Inc. (2.57%), Monaco Asset Management SAM (2.53%) and AQR Capital Management LLC (1.92%). Insiders that own company stock include Curet Myriam, Gil M Labrucherie, Gil M Labrucherie, Howard W Robin, Howard W Robin, Jillian B Thomsen, Jillian B Thomsen, John Northcott, Jonathan Zalevsky, Karin Eastham, Mark Andrew Wilson, Myriam Curet, Robert Chess and Roy A Whitfield.
View institutional ownership trends.
How do I buy shares of Nektar Therapeutics?: Shares of NKTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:NKTR) was last updated on 12/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial